Mela Sciences Inc (MELA) 1.12 $MELA Cipher Phar
Post# of 273257
Posted On: 09/03/2016 5:06:09 PM
Mela Sciences Inc (MELA) 1.12 $MELA
Cipher Pharmaceuticals Proposes Adding Rosemary A. Crane and Dr. Renee P. Tannenbaum To Board of Directors
CNW Group - Thu Apr 07, 6:00AM CDT
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company"
today announced that Rosemary A. (Rose) Crane and Dr. Renee P. Tannenbaum, two pharmaceutical industry leaders, are being proposed for election to Cipher's Board of Directors at the Company's Annual and Special Meeting on May 5, 2016.
CPH.TO: 5.68 (+0.22), MELA: 1.12 (+0.01), ZGNX: 8.02 (-0.16), CPHR: 4.33 (-0.06), ABBV: 64.12 (+0.09), TEVA: 51.22 (+0.32)
MELA Sciences Announces That Its Corporate Name Change to STRATA Skin Sciences Will Be Effective January 5, 2016
GlobeNewswire - Mon Jan 04, 12:00PM CST
MELA Sciences, Inc. (Nasdaq:MELA), today announced that its corporate name change to STRATA Skin Sciences, Inc. will be effective Tuesday, January 5, 2016 and that it will trade under the symbol "SSKN" on the Nasdaq Stock Market.
MELA: 1.12 (+0.01)
MELA Sciences Announces Corporate Name Change to STRATA Skin Sciences to Reflect Broader Dermatology Commitment
GlobeNewswire - Tue Dec 22, 7:00AM CST
MELA Sciences, Inc. (Nasdaq:MELA), today announced that it will be changing its corporate name to STRATA Skin Sciences, Inc. effective Tuesday, January 5, 2016 and that it will trade under the symbol "SSKN" on the Nasdaq Stock Market.
MELA: 1.12 (+0.01)
MELA Sciences Reports Supplemental Financial Information on XTRAC(R) Recurring Revenue
GlobeNewswire - Fri Nov 13, 1:21PM CST
MELA Sciences, Inc. (NASDAQ:MELA) reported today additional information related to its Third Quarter 2015 financial results press release dated November 12, 2015, clarifying the comparative revenue information from its XTRAC recurring revenues.
MELA: 1.12 (+0.01), PHMD: 0.22 (-0.02)
MELA Sciences promotes Christina L. Allgeier to CFO
M2 - Thu Nov 12, 3:58AM CST
Medical technology company MELA Sciences (NasdaqCM:MELA) reported on Wednesday that it has promoted Christina L. Allgeier to the position of chief financial officer.
MELA: 1.12 (+0.01)
MELA Sciences Appoints Christina L. Allgeier Chief Financial Officer
GlobeNewswire - Wed Nov 11, 1:52PM CST
MELA Sciences, Inc. (NASDAQ:MELA), a medical technology company dedicated to developing and commercializing innovative products for the treatment and diagnosis of serious dermatological disorders, today announced that Christina L. Allgeier has been promoted to the post of Chief Financial Officer of MELA Sciences, Inc., effective November 9, 2015. Ms. Allgeier is a graduate of Penn State University and is a Certified Public Accountant with significant SEC experience. Ms. Allgeier joined MELA as a result of the recent acquisition of the XTRAC and VTRAC business.
MELA: 1.12 (+0.01)
MELA Sciences to Report Third Quarter Financial Results on Thursday, November 12
GlobeNewswire - Thu Oct 29, 7:00AM CDT
MELA Sciences, Inc. (NASDAQ:MELA), a medical technology company dedicated to developing and commercializing innovative products for the diagnosis and treatment of serious dermatological disorders, will release third quarter financial results on Thursday, November 12, after the market close. MELA Sciences President and Chief Executive Officer, Michael Stewart, and Robert Cook, Chief Financial Officer, will host a conference call at 4:30pm Eastern Time to review the Company's progress and answer questions.
MELA: 1.12 (+0.01)
Intuitive Surgical Outshines Q3 Earnings Estimates, Stock Up
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 9:20AM CDT
Intuitive Surgical (ISRG) shares soar following company's impressive third quarter 2015 results.
ISRG: 688.37 (-1.32), MASI: 59.90 (+0.47), MELA: 1.12 (+0.01), MZOR: 22.23 (+0.37)
Remedy Pharmaceuticals Announces Appointment of Chief Financial Officer
BusinessWire - Wed Oct 14, 8:30AM CDT
Remedy Pharmaceuticals, a clinical stage pharmaceutical company focused on the development and commercialization of a revolutionary, breakthrough drug, CIRARA(TM), for treating acute central nervous system conditions -- where there are inadequate or no approved existing therapies -- announced today the appointment of Richard I. Steinhart as Chief Financial Officer effective immediately.
MELA: 1.12 (+0.01)
MELA Sciences Announces Election of R. Rox Anderson, M.D., to Board of Directors
GlobeNewswire - Tue Oct 13, 7:30AM CDT
MELA Sciences, Inc. (NASDAQ:MELA), a medical technology company dedicated to developing and commercializing innovative products for the diagnosis and treatment of serious dermatological disorders, announced today that R. Rox Anderson, M.D., was elected to the Company's board of directors at its Annual General Meeting of Stockholders held on September 30, 2015 in Philadelphia, PA. With Dr. Anderson's election, the MELA board of directors has increased to seven members, six of whom are independent.
MELA: 1.12 (+0.01)
Dermatology Diagnostic Devices Market - Technavio Unveils Global Trends & Forecast
BusinessWire - Thu Sep 24, 9:35AM CDT
Technavio has published a new report on the global dermatology diagnostic devices market, which is expected to grow at a CAGR of more than 9% from 2015-2019.
MELA: 1.12 (+0.01)
Is MELA Sciences an Incredible Momentum Stock? 3 Reasons Why MELA Will Be Tough to Beat
Zacks Equity Research - Zacks Investment Research - Tue Sep 22, 7:39AM CDT
MELA Sciences (MELA) is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions
MELA: 1.12 (+0.01)
MELA Sciences Reports Second Quarter 2015 Financial Results
GlobeNewswire - Thu Aug 13, 3:01PM CDT
MELA Sciences, Inc. (NASDAQ:MELA), a medical technology company dedicated to developing and commercializing innovative products for the diagnosis and treatment of serious dermatological disorders, today reported financial results for the second quarter ended June 30, 2015.
MELA: 1.12 (+0.01)
MELA Sciences to Report Second Quarter Financial Results on Thursday, August 13
GlobeNewswire - Wed Aug 12, 7:01AM CDT
MELA Sciences, Inc. (NASDAQ:MELA), a medical technology company dedicated to developing and commercializing innovative products for the diagnosis and treatment of serious dermatological disorders, will release second quarter financial results on Thursday, August 13, after the market close. MELA Sciences President and Chief Executive Officer, Michael Stewart, and Robert W. Cook, Chief Financial Officer, will host a conference call at 4:30pm Eastern Time to review the Company's progress and answer questions.
MELA: 1.12 (+0.01)
Hot Stock: MELA Sciences, Shares Drop 6.9% (MELA)
Comtex SmarTrend(R) - Fri Jun 26, 10:18AM CDT
MELA Sciences (NASDAQ:MELA) is one of today's worst performing low-priced stocks, down 6.9% to $1.22 on 1.1x average daily volume. MELA Sciences has traded 223,000 shares thus far today, vs. average volume of 207,000 shares per day. The stock has underperformed the Dow (-6.9% to the Dow's 0.4%) and underperformed the S&P 500 (-6.9% to the S&P's 0.1%) during today's trading.
MELA: 1.12 (+0.01)
North American Dermatology Treatment Devices Market 2015-2019 - Types (Liposuction, Microdermabrasion, Lasers) & Application (Cancer Diagnosis, Psoriasis, Hair Removal) Analysis
M2 - Tue May 26, 5:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g3tbwq/north_american) has announced the addition of the "North American Dermatology Treatment Devices Market by Types (Liposuction, Microdermabrasion, Lasers) & by Application (Cancer Diagnosis, Psoriasis, Hair Removal) - Forecast to 2019" report to their offering. The North American dermatology treatment devices market is estimated to grow at a CAGR of 10.1% from 2014 to 2019 The U.S holds the largest share of the dermatology treatment devices market; however, the Canadian market is expected to grow at the highest CAGR of 11.5% during the forecast period. Factors such as rising skin disorders, growing demand for diagnosis from the geriatric population, increasing demand for dermatologists, and technology advantages are driving market growth. However, factors such as lack of awareness, competitive pricing of devices, and lack of dermatology care are hindering the growth of this market. In this report, the North American dermatology treatment devices market has been broadly classified on the basis of types. This includes LED light therapy devices, lasers, electrosurgical equipment, liposuction devices, microdermabrasion, and cryotherapy. The lasers segment held the largest share in the treatment devices market, growing at a CAGR of 12.3% during the forecast period. Geographically, the U.S commanded the largest share of 86.0% of the North American dermatology treatment devices market in 2014, followed by Canada. The dermatology treatment devices market in the U.S. is primarily driven by increasing demand from the geriatric population and rise in insurance coverage among citizens due to increasing employment. Canada is the fastest-growing market in the North American region, growing at a CAGR of 11.5% during the forecast period. The North American dermatology treatment devices market is a competitive market with a number of market players. As of 2014, the North American dermatology treatment devices market is estimated to be dominated by Photomedex, Inc., Verisante technology, Inc., MELA Sciences, Inc., Michelson diagnostics Ltd, Leica Microsystems, Fotofinder systems GMBH, FEI Company, Solta medical, Syneron medical Ltd., Lumenis Ltd., Cutera, Inc., Cynosure, Inc., AMD global telemedicine Inc, Ambicare Health Ltd, and ALMA Lasers, Ltd. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Market Overview 5 North American Dermatology Treatment Devices Market, By Product 6 North American Dermatology Treatment Devices Market, By End User 7 North American Dermatology Treatment Devices Market, By Country 8 Dermatology Treatment Devices Market: Competitive Landscape 9 Dermatology Treatment Devices Market, By Company - ALMA Lasers, Ltd. - AMD Global Telemedicine Inc. - Ambicare Health Ltd - Cutera, Inc. - Cynosure, Inc. - FEI Company - Fotofinder Systems GMBH - LEICA Microsystems - Lumenis Ltd. - MELA Sciences, Inc. - Michelson Diagnostics Ltd. - Photomedex, Inc. - SOLTA Medical - Syneron Medical Ltd. - Verisante Technology, Inc. For more information visit http://www.researchandmarkets.com/research/g3...h_american
ELOS: 6.52 (-0.08), CYNO: 51.59 (-0.36), MELA: 1.12 (+0.01), LMNS: 13.76 (+0.04), FEIC: 106.61 (+0.05)
Traders Get Bullish on Shares of MELA Sciences, Shares Up 6.8% (MELA)
Comtex SmarTrend(R) - Thu May 21, 10:15AM CDT
MELA Sciences (NASDAQ:MELA) is one of today's best performing low-priced stocks, up 6.8% to $1.73 on 1.9x average daily volume. MELA Sciences has traded 385,000 shares thus far today, vs. average volume of 205,000 shares per day. The stock has outperformed the Dow (6.8% to the Dow's 0.0%) and outperformed the S&P 500 (6.8% to the S&P's 0.2%) during today's trading.
MELA: 1.12 (+0.01)
Cipher Pharmaceuticals Proposes Adding Rosemary A. Crane and Dr. Renee P. Tannenbaum To Board of Directors
CNW Group - Thu Apr 07, 6:00AM CDT
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company"
today announced that Rosemary A. (Rose) Crane and Dr. Renee P. Tannenbaum, two pharmaceutical industry leaders, are being proposed for election to Cipher's Board of Directors at the Company's Annual and Special Meeting on May 5, 2016. CPH.TO: 5.68 (+0.22), MELA: 1.12 (+0.01), ZGNX: 8.02 (-0.16), CPHR: 4.33 (-0.06), ABBV: 64.12 (+0.09), TEVA: 51.22 (+0.32)
MELA Sciences Announces That Its Corporate Name Change to STRATA Skin Sciences Will Be Effective January 5, 2016
GlobeNewswire - Mon Jan 04, 12:00PM CST
MELA Sciences, Inc. (Nasdaq:MELA), today announced that its corporate name change to STRATA Skin Sciences, Inc. will be effective Tuesday, January 5, 2016 and that it will trade under the symbol "SSKN" on the Nasdaq Stock Market.
MELA: 1.12 (+0.01)
MELA Sciences Announces Corporate Name Change to STRATA Skin Sciences to Reflect Broader Dermatology Commitment
GlobeNewswire - Tue Dec 22, 7:00AM CST
MELA Sciences, Inc. (Nasdaq:MELA), today announced that it will be changing its corporate name to STRATA Skin Sciences, Inc. effective Tuesday, January 5, 2016 and that it will trade under the symbol "SSKN" on the Nasdaq Stock Market.
MELA: 1.12 (+0.01)
MELA Sciences Reports Supplemental Financial Information on XTRAC(R) Recurring Revenue
GlobeNewswire - Fri Nov 13, 1:21PM CST
MELA Sciences, Inc. (NASDAQ:MELA) reported today additional information related to its Third Quarter 2015 financial results press release dated November 12, 2015, clarifying the comparative revenue information from its XTRAC recurring revenues.
MELA: 1.12 (+0.01), PHMD: 0.22 (-0.02)
MELA Sciences promotes Christina L. Allgeier to CFO
M2 - Thu Nov 12, 3:58AM CST
Medical technology company MELA Sciences (NasdaqCM:MELA) reported on Wednesday that it has promoted Christina L. Allgeier to the position of chief financial officer.
MELA: 1.12 (+0.01)
MELA Sciences Appoints Christina L. Allgeier Chief Financial Officer
GlobeNewswire - Wed Nov 11, 1:52PM CST
MELA Sciences, Inc. (NASDAQ:MELA), a medical technology company dedicated to developing and commercializing innovative products for the treatment and diagnosis of serious dermatological disorders, today announced that Christina L. Allgeier has been promoted to the post of Chief Financial Officer of MELA Sciences, Inc., effective November 9, 2015. Ms. Allgeier is a graduate of Penn State University and is a Certified Public Accountant with significant SEC experience. Ms. Allgeier joined MELA as a result of the recent acquisition of the XTRAC and VTRAC business.
MELA: 1.12 (+0.01)
MELA Sciences to Report Third Quarter Financial Results on Thursday, November 12
GlobeNewswire - Thu Oct 29, 7:00AM CDT
MELA Sciences, Inc. (NASDAQ:MELA), a medical technology company dedicated to developing and commercializing innovative products for the diagnosis and treatment of serious dermatological disorders, will release third quarter financial results on Thursday, November 12, after the market close. MELA Sciences President and Chief Executive Officer, Michael Stewart, and Robert Cook, Chief Financial Officer, will host a conference call at 4:30pm Eastern Time to review the Company's progress and answer questions.
MELA: 1.12 (+0.01)
Intuitive Surgical Outshines Q3 Earnings Estimates, Stock Up
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 9:20AM CDT
Intuitive Surgical (ISRG) shares soar following company's impressive third quarter 2015 results.
ISRG: 688.37 (-1.32), MASI: 59.90 (+0.47), MELA: 1.12 (+0.01), MZOR: 22.23 (+0.37)
Remedy Pharmaceuticals Announces Appointment of Chief Financial Officer
BusinessWire - Wed Oct 14, 8:30AM CDT
Remedy Pharmaceuticals, a clinical stage pharmaceutical company focused on the development and commercialization of a revolutionary, breakthrough drug, CIRARA(TM), for treating acute central nervous system conditions -- where there are inadequate or no approved existing therapies -- announced today the appointment of Richard I. Steinhart as Chief Financial Officer effective immediately.
MELA: 1.12 (+0.01)
MELA Sciences Announces Election of R. Rox Anderson, M.D., to Board of Directors
GlobeNewswire - Tue Oct 13, 7:30AM CDT
MELA Sciences, Inc. (NASDAQ:MELA), a medical technology company dedicated to developing and commercializing innovative products for the diagnosis and treatment of serious dermatological disorders, announced today that R. Rox Anderson, M.D., was elected to the Company's board of directors at its Annual General Meeting of Stockholders held on September 30, 2015 in Philadelphia, PA. With Dr. Anderson's election, the MELA board of directors has increased to seven members, six of whom are independent.
MELA: 1.12 (+0.01)
Dermatology Diagnostic Devices Market - Technavio Unveils Global Trends & Forecast
BusinessWire - Thu Sep 24, 9:35AM CDT
Technavio has published a new report on the global dermatology diagnostic devices market, which is expected to grow at a CAGR of more than 9% from 2015-2019.
MELA: 1.12 (+0.01)
Is MELA Sciences an Incredible Momentum Stock? 3 Reasons Why MELA Will Be Tough to Beat
Zacks Equity Research - Zacks Investment Research - Tue Sep 22, 7:39AM CDT
MELA Sciences (MELA) is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions
MELA: 1.12 (+0.01)
MELA Sciences Reports Second Quarter 2015 Financial Results
GlobeNewswire - Thu Aug 13, 3:01PM CDT
MELA Sciences, Inc. (NASDAQ:MELA), a medical technology company dedicated to developing and commercializing innovative products for the diagnosis and treatment of serious dermatological disorders, today reported financial results for the second quarter ended June 30, 2015.
MELA: 1.12 (+0.01)
MELA Sciences to Report Second Quarter Financial Results on Thursday, August 13
GlobeNewswire - Wed Aug 12, 7:01AM CDT
MELA Sciences, Inc. (NASDAQ:MELA), a medical technology company dedicated to developing and commercializing innovative products for the diagnosis and treatment of serious dermatological disorders, will release second quarter financial results on Thursday, August 13, after the market close. MELA Sciences President and Chief Executive Officer, Michael Stewart, and Robert W. Cook, Chief Financial Officer, will host a conference call at 4:30pm Eastern Time to review the Company's progress and answer questions.
MELA: 1.12 (+0.01)
Hot Stock: MELA Sciences, Shares Drop 6.9% (MELA)
Comtex SmarTrend(R) - Fri Jun 26, 10:18AM CDT
MELA Sciences (NASDAQ:MELA) is one of today's worst performing low-priced stocks, down 6.9% to $1.22 on 1.1x average daily volume. MELA Sciences has traded 223,000 shares thus far today, vs. average volume of 207,000 shares per day. The stock has underperformed the Dow (-6.9% to the Dow's 0.4%) and underperformed the S&P 500 (-6.9% to the S&P's 0.1%) during today's trading.
MELA: 1.12 (+0.01)
North American Dermatology Treatment Devices Market 2015-2019 - Types (Liposuction, Microdermabrasion, Lasers) & Application (Cancer Diagnosis, Psoriasis, Hair Removal) Analysis
M2 - Tue May 26, 5:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g3tbwq/north_american) has announced the addition of the "North American Dermatology Treatment Devices Market by Types (Liposuction, Microdermabrasion, Lasers) & by Application (Cancer Diagnosis, Psoriasis, Hair Removal) - Forecast to 2019" report to their offering. The North American dermatology treatment devices market is estimated to grow at a CAGR of 10.1% from 2014 to 2019 The U.S holds the largest share of the dermatology treatment devices market; however, the Canadian market is expected to grow at the highest CAGR of 11.5% during the forecast period. Factors such as rising skin disorders, growing demand for diagnosis from the geriatric population, increasing demand for dermatologists, and technology advantages are driving market growth. However, factors such as lack of awareness, competitive pricing of devices, and lack of dermatology care are hindering the growth of this market. In this report, the North American dermatology treatment devices market has been broadly classified on the basis of types. This includes LED light therapy devices, lasers, electrosurgical equipment, liposuction devices, microdermabrasion, and cryotherapy. The lasers segment held the largest share in the treatment devices market, growing at a CAGR of 12.3% during the forecast period. Geographically, the U.S commanded the largest share of 86.0% of the North American dermatology treatment devices market in 2014, followed by Canada. The dermatology treatment devices market in the U.S. is primarily driven by increasing demand from the geriatric population and rise in insurance coverage among citizens due to increasing employment. Canada is the fastest-growing market in the North American region, growing at a CAGR of 11.5% during the forecast period. The North American dermatology treatment devices market is a competitive market with a number of market players. As of 2014, the North American dermatology treatment devices market is estimated to be dominated by Photomedex, Inc., Verisante technology, Inc., MELA Sciences, Inc., Michelson diagnostics Ltd, Leica Microsystems, Fotofinder systems GMBH, FEI Company, Solta medical, Syneron medical Ltd., Lumenis Ltd., Cutera, Inc., Cynosure, Inc., AMD global telemedicine Inc, Ambicare Health Ltd, and ALMA Lasers, Ltd. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Market Overview 5 North American Dermatology Treatment Devices Market, By Product 6 North American Dermatology Treatment Devices Market, By End User 7 North American Dermatology Treatment Devices Market, By Country 8 Dermatology Treatment Devices Market: Competitive Landscape 9 Dermatology Treatment Devices Market, By Company - ALMA Lasers, Ltd. - AMD Global Telemedicine Inc. - Ambicare Health Ltd - Cutera, Inc. - Cynosure, Inc. - FEI Company - Fotofinder Systems GMBH - LEICA Microsystems - Lumenis Ltd. - MELA Sciences, Inc. - Michelson Diagnostics Ltd. - Photomedex, Inc. - SOLTA Medical - Syneron Medical Ltd. - Verisante Technology, Inc. For more information visit http://www.researchandmarkets.com/research/g3...h_american
ELOS: 6.52 (-0.08), CYNO: 51.59 (-0.36), MELA: 1.12 (+0.01), LMNS: 13.76 (+0.04), FEIC: 106.61 (+0.05)
Traders Get Bullish on Shares of MELA Sciences, Shares Up 6.8% (MELA)
Comtex SmarTrend(R) - Thu May 21, 10:15AM CDT
MELA Sciences (NASDAQ:MELA) is one of today's best performing low-priced stocks, up 6.8% to $1.73 on 1.9x average daily volume. MELA Sciences has traded 385,000 shares thus far today, vs. average volume of 205,000 shares per day. The stock has outperformed the Dow (6.8% to the Dow's 0.0%) and outperformed the S&P 500 (6.8% to the S&P's 0.2%) during today's trading.
MELA: 1.12 (+0.01)
(0)
(0)Scroll down for more posts ▼